PMC:7408073 / 100086-100254 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":38,"end":53},"obj":"Body_part"},{"id":"T2","span":{"begin":82,"end":87},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma317863"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma7199"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T195","span":{"begin":38,"end":53},"obj":"Body_part"}],"attributes":[{"id":"A195","pred":"uberon_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/UBERON_0001555"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3477","span":{"begin":163,"end":167},"obj":"Gene"},{"id":"3480","span":{"begin":69,"end":95},"obj":"Disease"},{"id":"3481","span":{"begin":97,"end":118},"obj":"Disease"}],"attributes":[{"id":"A3477","pred":"tao:has_database_id","subj":"3477","obj":"Gene:59272"},{"id":"A3480","pred":"tao:has_database_id","subj":"3480","obj":"MESH:D015212"},{"id":"A3481","pred":"tao:has_database_id","subj":"3481","obj":"MESH:D005756"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T555","span":{"begin":54,"end":67},"obj":"Disease"},{"id":"T556","span":{"begin":69,"end":95},"obj":"Disease"},{"id":"T557","span":{"begin":97,"end":106},"obj":"Disease"},{"id":"T558","span":{"begin":111,"end":118},"obj":"Disease"}],"attributes":[{"id":"A555","pred":"mondo_id","subj":"T555","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A556","pred":"mondo_id","subj":"T556","obj":"http://purl.obolibrary.org/obo/MONDO_0005265"},{"id":"A557","pred":"mondo_id","subj":"T557","obj":"http://purl.obolibrary.org/obo/MONDO_0004966"},{"id":"A558","pred":"mondo_id","subj":"T558","obj":"http://purl.obolibrary.org/obo/MONDO_0005292"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T3","span":{"begin":38,"end":53},"obj":"http://purl.obolibrary.org/obo/UBERON_0001555"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T3495","span":{"begin":4,"end":18},"obj":"Chemical"}],"attributes":[{"id":"A91673","pred":"chebi_id","subj":"T3495","obj":"http://purl.obolibrary.org/obo/CHEBI_52217"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T1","span":{"begin":54,"end":67},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-sentences","denotations":[{"id":"T484","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T162","span":{"begin":69,"end":95},"obj":"Phenotype"},{"id":"T163","span":{"begin":97,"end":106},"obj":"Phenotype"},{"id":"T164","span":{"begin":111,"end":118},"obj":"Phenotype"}],"attributes":[{"id":"A162","pred":"hp_id","subj":"T162","obj":"http://purl.obolibrary.org/obo/HP_0002037"},{"id":"A163","pred":"hp_id","subj":"T163","obj":"http://purl.obolibrary.org/obo/HP_0005263"},{"id":"A164","pred":"hp_id","subj":"T164","obj":"http://purl.obolibrary.org/obo/HP_0002583"}],"text":"Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2."}